Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM-CARE: RadioEmbolization + CisGem + Durvalumab in Unresectable Cholangiocarcinoma
NCT06375915Phase 2Recruiting
- Start
- Apr 2024
- Primary completion
- May 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in intrahepatic cholangiocarcinoma (ICC). Started Apr 2024; status: recruiting.
02
Drugs
durvalumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT06375915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06375915.